| 國立成功大學 |
2023 |
Prospective, open-label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study
|
Yang, T.-S.;Chen, H.-H.;Bo-Wen, L.;Kim, T.W.;Kim, J.G.;Ahn, J.B.;Lee, M.-A.;Lin, J.;Ho, G.F.;Anh, L.T.;Temraz, S.;Burge, M.;Chua, Chua C.;Huang, J.;Park, Y.S. |
| 臺大學術典藏 |
2022-09-15T01:08:51Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Chia-Chi Lin; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; Hsu C. |
| 臺大學術典藏 |
2022-08-19T00:20:57Z |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
Cheng A.-L.; Meng R.; Chao Y.; Hsieh T.-Y.; Huang W.-T.; Hwang W.-S.; Yu C.-W.; Hsieh R.-K.; Huo T.-I.; Yang T.-S.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:31Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Lin C.-C.; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-12T06:28:05Z |
Long-Term Survival of HLA-DR15+ Pig Skin in SCID Mice After Reconstitution With Human Peripheral Blood Mononuclear Cells and Under Short-Term Immunosuppression
|
Tai H.-C.; Tu C.-F.; Lee J.-M.; Ho L.-L.; Tseng Y.-L.; Chou N.-K.; Yang T.-S.; Weng C.-N.; Lee P.-H.; KING-JEN CHANG; Tang Y.-B. |
| 臺大學術典藏 |
2022-06-10T06:11:12Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; ZHONG-ZHE LIN; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2022-05-13T08:04:23Z |
Healthcare-associated infections in intensive care units in Taiwan, South Korea, and Japan: Recent trends based on national surveillance reports
|
Chiang C.-H.; Pan S.-C.; Yang T.-S.; Matsuda K.; Kim H.B.; Choi Y.H.; Hori S.; JANN-TAY WANG; Sheng W.-H.; Chen Y.-C.; Chang F.-Y.; Chang S.-C. |
| 國立成功大學 |
2022 |
Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety
|
Shao, Y.-Y.;Feng, Y.-H.;Yen, C.-J.;Yang, T.-S.;Shen, Y.-C.;Chao, Y.;Chen, J.-S.;Su, C.-Y.;Chen, W.-J.;Hsiang, Hsiang H.-L.;Hsu, C.-H. |
| 臺大學術典藏 |
2021-09-15T01:20:51Z |
Quantitative Proteomics of Th-MYCN Transgenic Mice Reveals Aurora Kinase Inhibitor Altered Metabolic Pathways and Enhanced ACADM to Suppress Neuroblastoma Progression
|
Hsieh C.-H.; Cheung C.H.Y.; Liu Y.-L.; Hou C.-L.; CHIA-LANG HSU; Huang C.-T.; Yang T.-S.; Chen S.-F.; Chen C.-N.; Hsu W.-M.; Huang H.-C.; Juan H.-F. |
| 臺大學術典藏 |
2021-09-01T01:54:24Z |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
|
ANN-LII CHENG; Kang Y.-K.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Luo R.; Feng J.; Ye S.; Yang T.-S.; Xu J.; Sun Y.; Liang H.; Liu J.; Wang J.; Tak W.Y.; Pan H.; Burock K.; Zou J.; Voliotis D.; Guan Z. |
